Rapid tamoxifen-induced inactivation of an estrogenic response is accompanied by a localized epigenetic modification but not by mutations

Breast Cancer Research and Treatment

Volumn 47, Issue 1, 1998, Pages 71-81

  Badia, Eric ^a   Duchesne, Marie Josephe ^a   Nicolas, Jean Claude ^a   Pons, Michel ^a  

^a INSERM   (France)

Author keywords

4 hydroxytamoxifen; Estrogenic response; MCF 7 derived cells; Methylation; Silencing

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CPG ISLAND; DEVELOPMENTAL GENETICS; DNA METHYLATION; DRUG HALF LIFE; GENE MUTATION; GENOTOXICITY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION;

BREAST NEOPLASMS; DNA METHYLATION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LUCIFERASES; MUTATION; PLASMIDS; PROMOTER REGIONS (GENETICS); TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031964203     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005801005966     Document Type: Article

References (40)

1. Cole MP, Jones CT, Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 25: 270-275, 1971
2. Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE: Tamoxifen. In: Goldberg ME (ed) Pharmacological and Biochemical Properties of Drug Substances. Vol 2. American Pharmaceutical Association, Washington, 1979, pp 355-399
3. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variants contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31: 129-138, 1994
4. Zhang Q-X, Borg A, Fuqua SAW: An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res 53: 5882-5884, 1993
5. Osborne CK, Coronado E, Allred DC, Wiebe V, De Gregorio M: Acquired tamoxifen resistance: correlation with reduced tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482, 1991
6. Dickson RB, Lippman ME: Growth factors in breast cancer. Endocr Rev 16: 559-589, 1995
7. Horwitz KB: How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol 49: 295-302, 1994
8. Fujimoto N, Katzenellenbogen BS: Alterations in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol Endocrinol 8: 296-304, 1994
9. Astruc ME, Chabret C, Bali P, Gagne D, Pons M: Prolonged treatment of breast cancer cells with antiestrogens increases API-mediated response: involvement of the estrogen receptor. Endocrinology 136: 824-832, 1995
10. Morrow M, Jordan VC: The prevention of breast cancer with tamoxifen. In: Jordan VC (ed) Long-term Tamoxifen Treatment for Breast Cancer. The University of Wisconsin Press, Madison, pp 257-278, 1994
11. Badia E, Duchesne M-J, Fournier-Bidoz S, Simar-Blanchet AE, Terouanne B, Nicolas J-C, Pons M: Hydroxytamoxifen induces a rapid and irreversible inactivation of an estrogenic response in an MCF-7 derived cell line. Cancer Res 54: 5860-5866, 1994
12. Pons M, Gagne D, Nicolas J-C, Mehtali M: A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Bio Techniques 9: 450-459, 1990
13. Kim U: Factors influencing the generation of phenotypic heterogeneity in mammary tumors. In: Mihich E (ed) Biological Responses in Cancer 4. Plenum Press, New York, 1985, pp 91-124
14. Daly RJ, Darbre PD: Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res 50: 5868-5875, 1990
15. R-1. Cancer Res 54: 1587-1595, 1994
16. Cedar H: DNA methylation and gene activity. Cell 53: 3-4, 1988
17. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995
18. Falette NS, Fuqua SAW, Chamness GC, Cheal MS, Greene GL, McGuire WL: Estrogen receptor gene methylation in human breast tumors. Cancer Res 50: 3974-3978, 1990
19. Darbre P, King RJB: Progression to steroid autonomy in S115 mouse mammary tumor cells: role of DNA methylation. J Cell Biol 99: 1410-1415, 1984
20. Bowie LJ: Synthesis of firefly luciferin and structural analogs. Methods in Enzymology. Academic Press, New York, LVII, 1978, pp 15-28
21. 2 gene functions in transfected human cells. Cell 46: 1053-1061, 1986
22. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89: 1827-1831, 1992
23. Raizis AM, Schmitt F, Jost JP: A bisulfite method of 5-methylcytosine mapping that minimizes template degradation. Anal Biochem 226: 161-166, 1995
24. Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363, 1992
25. Martin EA, Rich KJ, White INH, Woods KL, Powles TJ, Smith LL: P-32-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16: 1651-1654, 1995
26. Hemminki K, Widlak P, Hou SM: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16: 1661-1664, 1995
27. Cai QY, Wei HC: In vivo formation of DNA-adducts in mouse skin DNA by tamoxifen. Cancer Lett 92: 187-192, 1995
28. McClelland M, Nelson M, Raschke E: Effect of site-specific modification on restriction endonucleases and DNA modification methyltransferases. Nucl Acids Res 22: 3640-3659, 1994
29. Hatada I, Hayashizaki Y, Hirotsune S, Komatsubara H, Mukai T: A genomic scanning method for higher organisms using restriction sites as landmarks. Proc Natl Acad Sci USA 88: 9523-9527, 1991
30. Ben-Hattar J, Beard P, Jiricny J: Cytosine methylation in CTF and Sp1 recognition sites of an HSV tk promoter: effects on transcription in vivo and on factor binding in vivo. Nucl Acids Res 17: 10179-10190, 1989
31. Graessmann A, Sandberg G, Graessmann M: Methylation of single sites within the Herpes simplex virus tk coding region and the Simian virus 40 T-antigen intron causes gene inactivation. Mol Cell Biol 14: 2004-2010, 1994
32. Yokomori N, Kobayashi R, Moore R, Sueyoshi T, Negishi MA: DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP. Mol Cell Biol 15: 5355-5362, 1995
33. Iguchi-Ariga SMH, Schaffner W: CpG methylation of the cAMP responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 3: 612-619, 1989
34. Boyes J, Bird A: DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64: 1123-1134, 1991
35. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, Chambon P: A possible involvement of TIF1α and TIF1β in the epigenetic control of transcription by nuclear receptors. EMBO J 15: 6701-6715, 1996
36. Herschbach BM, Johnson AD: Transcriptional repression in eukaryotes. Annu Rev Cell Dev Biol 9: 479-509, 1993
37. Loo S, Rine J: Silencing and heritable domains of gene expression. Annu Rev Cell Dev Biol 11: 519-548, 1995
38. Robertson G, Garrick D, Wu W, Kearns M, Martin D, Whitelaw E: Position-dependent variegation of globin transgene expression in mice. Proc Natl Acad Sci USA 92: 5371-5375, 1995
39. Walters MC, Magis W, Fiering S, Eidemiller J, Scalzo D, Groudine M, Martin DIK: Transcriptional enhancers act in cis to suppress position-effect variegation. Genes Dev 10: 185-195, 1996
40. Lowry OH, Rosebrough NI, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951